Revolutionary Cancer Treatment Could Be Available by 2027

A groundbreaking cancer treatment developed in Wellington may soon be accessible to patients through the public health system, potentially by 2027. This innovative therapy, known as CAR T-cell therapy, has shown remarkable success in putting patients with terminal cancer into long-term remission. The biotech company behind this development, BioOra Limited, is preparing for rapid production of the treatment, pending regulatory approval.

BioOra, partially owned by the Malaghan Institute of Medical Research, is working to manufacture CAR T-cell therapy for both public and private healthcare systems. Currently, patients seeking this treatment often pay exorbitant costs in countries like China. The company aims to establish a state-of-the-art manufacturing facility in Christchurch to produce the therapy at scale, ensuring safety and precision.

Managing Director John Robson has expressed concern about the pace of approval from health officials. He noted, “We’re kind of on this knife edge of, will they go fast enough for us? Quarter 1 of 2027 is a distinct possibility for public access, but it has to dovetail with a funding stream.” Delays could lead to the treatment being offered privately instead, as discussions are already underway with interested providers.

Understanding CAR T-cell Therapy

CAR T-cell therapy involves extracting a patient’s immune cells, genetically modifying them to target and destroy cancer cells, and then reinfusing them into the patient’s bloodstream. This approach has become a standard treatment for certain blood cancers in countries like Australia but remains unavailable in New Zealand.

The Malaghan Institute has developed its own CAR T formulation, which has produced promising results in a phase 1 clinical trial. Over half of the lymphoma patients involved, who had exhausted other treatment options, achieved complete remission within months, with significantly fewer serious side effects compared to existing therapies available internationally. This advancement suggests that the local CAR T treatment could be administered on an outpatient basis, reducing overall costs per patient.

Phase 2 of the trial is set to enroll its final patient with large B-cell lymphoma in October, with the results crucial for obtaining Medsafe approval. BioOra, which emerged from the Malaghan Institute, is currently producing CAR T for trials in Wellington but is raising substantial funds to establish its new facility in Christchurch.

Future Prospects and Challenges

The planned manufacturing site will adhere to Good Manufacturing Practice (GMP) standards, ensuring the highest safety and quality in drug production, and is expected to create approximately 45 to 50 jobs in Christchurch. Robson indicated that the facility should be certified and operational by late 2026 to align with trial completion. Initially, the goal is to manufacture CAR T for 160 patients in the first year, with projections to exceed 300 in the second year.

Securing public access to the therapy will necessitate special governmental funding alongside ongoing private investment. Robson noted that while he could not disclose the exact cost per patient, it would be significantly lower than the average $1 million charged in markets like Australia and the United States.

The economic rationale for public investment is clear. A one-off treatment could save the healthcare system millions compared to prolonged hospital stays and costly interventions such as stem cell transplants and chemotherapy. Robson emphasized, “If you have a 20 or 30-year-old treated and they effectively go down this curative pathway, then their benefit and their input to New Zealand is huge.”

The Cancer Control Agency, known as Te Aho o Te Kahu, is overseeing the official response to CAR T-cell therapy. Its acting chief executive, Nicola Hill, stated that new legislation, the Medical Products Bill, will introduce flexible approval pathways for treatments like CAR T-cell therapy. However, the implementation of this framework is not expected until late 2030.

As BioOra continues to explore opportunities for growth, including possible manufacturing facilities in Australia, the company aims to position itself as a leader in immunotherapy. Robson envisions a future where patients from abroad travel to New Zealand for this innovative treatment, furthering the nation’s capabilities in medical tourism.

With the launch of a campaign to raise funds for the phase 2 trial, which is projected to cost over $17 million, the Malaghan Institute is committed to advancing this life-changing therapy. As BioOra navigates the complexities of regulatory approval and funding, the hope for many patients lies in the potential for timely access to a treatment that could alter the course of their lives.